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Abstract
Background: Acute respiratory infections (ARIs), caused by the high level of immaturity of the immune system, are a
major cause of morbidity in preterm newborns. The probiotic Escherichia coli strain Nissle 1917 (EcN) is well known for
its immuno-modulatory properties and may therefore enhance the immune competence. Thus, EcN administration
may provide a promising possibility to decrease the risk of ARIs in this vulnerable group of children. However, clinical
data supporting or refuting this hypothesis are, to our knowledge, not available. Therefore, the aim of the presented
pilot trial was to collect first data on the efficacy and safety of EcN treatment to prevent ARIs in late preterm newborns.
Methods: Right after birth, 62 late preterm newborns were included into an open-labeled, controlled 4-week trial with
two parallel groups and a follow-up phase until the age of 1 year. All children of the treatment group received an EcN
suspension orally for 3 weeks, whereas the control group was only observed. Primary efficacy variable was the number
of participants with at least one ARI during the first 28 days of life. Secondary efficacy variables were the number of
ARIs and the number and duration of hospitalizations caused by ARIs during the first year of life.
Results: The number of participants with at least one ARI during the first 28 days of life was significantly lower in the
group treated with EcN compared to that in the control group. Although only of exploratory nature, analyses of
secondary efficacy variables suggest that EcN treatment may also reduce the average number of ARIs, the
average number of hospitalizations caused by ARIs, and the mean duration of such hospitalizations. There is
also some evidence that early EcN treatment may have long-term benefits on newborns’ health status.
Conclusion: The present pilot trial provides first evidence that EcN is able to reduce the incidence of ARIs in
the neonatal period of late preterm newborns. Additionally, EcN is characterized by an excellent individual
biocompatibility in the absence of adverse drug reactions. Limitations of the current trial are discussed and
recommendations for future confirmatory studies are made.
Trial registration: ClinicalTrials.gov identifier: NCT01540162; retrospectively registered on 16 February 2012
Keywords: Immunity improvement, Acute respiratory infection, E. coli Nissle, Late preterm newborn, Prophylaxis
* Correspondence: acadanl@rambler.ru
1Odessa National Medical University, 2 Valihovsky Lane, Odessa 65082,
Ukraine
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Aryayev et al. Pilot and Feasibility Studies  (2018) 4:79 
https://doi.org/10.1186/s40814-018-0271-y
Background
Acute respiratory infections (ARIs) are one of the most
important causes of morbidity and mortality among
newborns and infants. Due to their immature immune
system, newborn infants show a high vulnerability with
an average of about four ARIs during the first year of
life [1]. This number may be even higher in infants that
were born preterm, and some data suggest that ARIs
are the main reason for the rehospitalization of these
children [2]. Humoral immunity deficiency in newborns
is caused by insufficient transplacental transfer of IgG
and a lack of IgA and IgM in serum [3]. Insufficient ac-
tivation of complement systems and low concentration
of its components lead to a low opsonic activity of
blood and weakness of phagocytes [3]. Immaturity of
bone marrow cells may often result in neutropenia [3].
Low sensitivity of T lymphocyte receptors to IL-1 and
IL-2; T helper cells immaturity and poor interaction of
T and B lymphocytes, resulting in low levels of antibody
production in response to antigens; and insufficient
production of interferon γ by CD4+ T cells define a
weak resistance of preterm newborns against the
bacterial flora, a trend to spreading of infections and a
high susceptibility to viral infections [3].
A link between the newborns’ health status, the
state of its intestinal flora, and immunity, respectively,
was shown by several researchers [4–7]. The intestinal
bacterial colonization in preterm infants depends on a
number of factors—vaginal microbiota of the mother,
breastfeeding profile, the conditions in the maternity
hospital, perinatal pathological factors, nosocomial
flora, and the use of antibiotics and other pharma-
ceutical agents. The microbiocoenosis is incomplete at
the end of the adaptation period of preterm infants
and this, in turn, is a basic principle for bacterial and
viral infections [3].
In modern neonatology, probiotics are widely used in
daily practice. Probiotics consist of “live microorgan-
isms which when administered in adequate amounts
confer a health benefit on the host” [8]. Several studies
indicate that administering probiotics can have a favor-
able effect on the prevention of infections [9–13], al-
though a series of randomized controlled trials also
suggests that effects observed in one probiotic strain
cannot be extrapolated to others [14, 15].
The probiotic Escherichia coli strain Nissle 1917 (EcN)
has no pathogenic characteristics [16], is non-invasive [17],
and is capable to colonize the intestinal tract for longer pe-
riods [18–20]. Due to its wide spectrum of positive and
clinically relevant characteristics and its great tolerance
[21–26], EcN has been approved as a medical drug under
the brand name Mutaflor® Suspension (Ardeypharm
GmbH, Herdecke, Germany) in various countries,
including the Ukraine.
One particularly interesting and important property
of EcN is its broad immunomodulatory effect on the
non-specific and specific immunological system. EcN
stimulates the systemic production of antibodies of
mucous-associated B lymphocytes and induces the sys-
temic production of antibodies (IgM, IgA) in adults as
well as in full-term and premature children [27–30].
Interestingly, early administration of secretory IgA anti-
bodies can protect children from infections [31]. In
combination, these findings make it reasonable to as-
sume that EcN may increase the immune competence
in preterm newborn infants, thereby reducing the risk
of acquiring infections. However, clinical data support-
ing or refuting this hypothesis are, to our knowledge,
not available. Therefore, the aim of the present pilot
trial was to collect first data on the efficacy and safety
of EcN treatment to prevent ARIs in late preterm
newborns.
Methods
Study design and conduct
The present trial was a monocentric, prospective, and
open-labelled clinical trial with a corresponding un-
treated control group, conducted in Odessa, Ukraine.
The trial consisted of two parts, a newborn phase (time
point of inclusion until day 28 of life) and a follow-up
phase (day 29 of life until the end of the first year of
life). Criteria for trial entry were signed informed con-
sent of the child’s legal guardian(s), first degree of pre-
maturity (i.e., functionally mature and gestational age
35–36 weeks), intention of the mother to exclusively
breast-feed her child during the newborn phase of the
trial, and a newborn’s age of 12–24 h of life at enroll-
ment. Infants were excluded in case of non-fulfilment of
one inclusion criteria, perinatal asphyxia or any perinatal
pathological disease or defect (e.g., congenital birth de-
fect, perinatal encephalopathy, other infectious disease,
respiratory distress syndrome, and TORCH infections
(Toxoplasmosis; Other, i.e., syphilis, varicella-zoster,
parvovirus B19; Rubella; Cytomegalovirus; and Herpes
infections [32])), blood analysis results with clinically sig-
nificant changes (i.e., deviations from mean values larger
than ± 2 SD that are probably or possibly related to any
underlying pathological condition), or intention to feed
the child other pro- or prebiotics during the newborn
phase of the trial. Eligible preterm newborns that were
born in Odessa Maternity Hospital No. 5, Odessa,
Ukraine, were included in this trial. Further examina-
tions were carried out in health care centers of the
Odessa region.
Enrolled children were either assigned to the treatment
group (EcN) or the control group in an alternating man-
ner by each participating investigator. Infants of the treat-
ment group received an orally administered daily dosage
Aryayev et al. Pilot and Feasibility Studies  (2018) 4:79 Page 2 of 9
of 1 ml Mutaflor® Suspension, containing 108 colony-
forming units of E. coli strain Nissle 1917 per milliliter,
during the first 7 days of life, and 1 ml of the same suspen-
sion three times a week from day 8 to 21. Thus, the appli-
cation of Mutaflor® Suspension complied with the dosage
scheme of the approved medical product. Infants of the
control group remained untreated and were just observed.
The trial comprised an initial examination (day 0),
during which clinical, demographic, and somatic char-
acteristics of the newborn were recorded (Table 1).
During the newborn phase, visits were carried out on
days 7 and 21, and phone contacts took place on days
14 and 28. The follow-up observations took place as
part of the conventional preventive checkups carried
out at the ages of 6 and 12 months in Ukraine. Efficacy
and safety data were recorded based on hospital med-
ical records (if available) and parental reporting. A flow
chart is presented in Fig. 1.
The primary variable to assess efficacy of EcN for im-
munity improvement in preterm newborns was the
number of participants with at least one acute respira-
tory infection during the newborn phase, i.e., during the
first 28 days of life. Acute rhinitis, acute rhinopharyngi-
tis, acute bronchitis, acute bronchiolitis, and pneumonia
were counted as ARIs. As secondary efficacy variables,
the number of ARI events and the number and duration
of hospitalizations caused by ARIs during the newborn
phase were documented. A further secondary objective
of the present trial was to explore whether early EcN
treatment has also a long-term effect on infant immun-
ity. Therefore, all measures were also taken at the ages
of 6 and 12 months.
The safety of EcN was evaluated by quantifying the
number of adverse events (AEs) throughout the entire
trial period, i.e., all untoward medical occurrences except
the ARIs considered as primary efficacy variables. AEs
were regarded as drug related if causality due to the
study medication was rated “certain,” “probable,” or
“possible” (according to the WHO Collaborating Centre
for International Drug Monitoring) by the investigators.
As a further safety measure, the somatic development,
quantified by body weight and body length, was re-
corded at the ages of 6 and 12 months.
Figure 1 provides an overview of the points in time
when efficacy and safety measures were taken.
Participants’ sufficient compliance to the trial protocol
was defined as a complete lack of treatment with respect
to the study medication for participants of the control
group and an intake of at least 75% of the planned trial
medication for participants of the treatment group.
Statistical analysis
Counts, means, frequencies, standard deviations, and 95%
confidence intervals were calculated for the recorded data
according to applicability. The data used to calculate the
values at 6 months of life also contained the data already
recorded during the first 28 days. Similarly, reported
values after 12 months of life were calculated from all the
data collected between the time of inclusion and
12 months of life.
Categorical data were compared by applying chi-
square tests with Yates’s correction and quantitative data
by using the Mann-Whitney U tests.
The relative risk (RR), the relative risk reduction (RRR),
and the number needed to treat (NNT) were calculated
from the “number of participants with at least one ARI”.
Analyses were performed in Statistica 7.0 or Microsoft
Excel and the significance level α was set at p < 0.05.
Results
Participants
Between 19 March and 15 September 2011, a total of 62
late preterm newborns of Caucasian race were included
into the trial and either assigned to the EcN (N = 30) or
the control (N = 32) group (Fig. 2). The follow-up of the
last participant ended on the 12 October 2012. On aver-
age, children of the two trial arms showed no substantial
differences in any of the clinical, demographic, or som-
atic characteristics recorded during initial examination
(Table 1). All participants complied with the trial proto-
col, such that ITT and PP analyses of all data revealed
equal results.
Efficacy and safety of EcN for immunity improvement in
late preterm newborns during the first 28 days of life
(newborn phase)
Analysis of the primary outcome measure revealed a sig-
nificant difference between the two trial arms, with
fewer participants suffering from at least one ARI during
Table 1 Baseline characteristics of children enrolled in the study
of efficacy and safety of EcN for immunity improvement in late
preterm newborns
Characteristics EcN (N = 30) Control (N = 32)
Gestational age at birth (weeks) 35.5 ± 0.5 35.5 ± 0.5
Age at inclusion (hours) 17.3 ± 3.8 17.4 ± 3.3
Sex Female 14 (46.7) 15 (46.9)
Male 16 (53.3) 17 (53.1)
Type of birth Vaginal 28 (93.3) 26 (81.3)
Caesarean 2 (6.7) 6 (18.8)
Birth weight (g) 2400 ± 122 2396 ± 77
Birth length (cm) 45.2 ± 0.8 45.2 ± 0.9
APGAR scores I 7.5 ± 0.5 7.6 ± 0.6
II 8.1 ± 0.3 8.1 ± 0.3
Data are mean ± SD or number (%)
SD standard deviation, APGAR score Appearance, Pulse, Grimace, Activity,
Respiration score
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the first 28 days of life in the EcN than in the control
group (Fig. 3, Table 2). The risk to contract an ARI dur-
ing the first month of life was 77% lower in the EcN
than that in the control group, and the corresponding
number needed to treat was 3.
Furthermore, exploratory comparisons suggest that
the average number of ARIs, the average number of hos-
pitalizations caused by ARIs, and the mean duration of
such hospitalizations were lower in the group treated
with EcN compared to the control group (Fig. 4, Table 2).
Table 3 provides an overview of the type and number of
ARIs that occurred.
During the first 28 days of life, none of the children in
the EcN group suffered from an AE, whereas six adverse
events were recorded in the control group (Table 2; kind
of AE (no. of occurrences in EcN group/no. of occur-
rences in control group): infant colic (0/3); constipation
(0/1); diarrhea (0/1); diaper dermatitis (0/1)).
Efficacy and safety of EcN for immunity improvement in
late preterm newborns during the first year of life
(follow-up phase)
Explorative analyses of the data obtained after 6 and
12 months of life revealed that the risk to suffer from an
ARI was still 30 and 18% lower in the EcN group com-
pared to that in the untreated control group (Table 2).
However, the number of participants that experienced at
least one ARI did not show any meaningful difference
between the EcN and the control group anymore, nei-
ther after 6 nor after 12 months of life (Table 2).
Fig. 1 Flowchart showing the timeline of the trial and the measurement schedule. ARI acute respiratory infection
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In contrast, the average number of ARI events and the
average number and duration of hospitalizations caused
by ARIs mostly appeared to be still different between the
two trial arms, with the EcN group having a health ad-
vantage over the control group (Fig. 4, Table 2). Table 3
provides an overview of the type and number of ARIs
that occurred.
The number of AEs reported during the entire trial
was not considerably different (Table 2; kind of AE (no.
of occurrences in EcN group/no. of occurrences in con-
trol group): at 12 months of age: infant colic (7/6); acute
enterocolitis (2/3); constipation (5/4); diarrhea (0/1); re-
gurgitation (2/3); acute otitis media (2/2); diaper derma-
titis (0/1); atopic dermatitis (3/2); changed blood
parameter (0/1); weight deficiency (2/2); iron deficiency
anemia stage 1 (2/3); perinatal encephalopathy; diag-
nosed only 3–5 weeks after inclusion into the trial (3/
2)). Importantly, the investigators judged none of the ad-
verse events as related to treatment. Children’s somatic
development, quantified by body weight and body
length, was according to age [33] and comparable be-
tween the two trial arms (Table 2).
Discussion
The present pilot trial provides first evidence that
Escherichia coli strain Nissle 1917 is an effective and safe
probiotic that may improve immune competence in late
preterm newborns. The evaluation of the primary
Fig. 2 Flowchart showing the allocation of subjects
Fig. 3 Result of primary efficacy measure. Shown are the numbers of participants with at least one ARI during the first 28 days of life for the EcN
and the control group, respectively
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efficacy criterion revealed that treatment of late preterm
newborns with EcN suspension reduced their risk to
contract an ARI during the first 28 days of life by 77% in
comparison to children that remained untreated, a re-
duction that is substantial and clinically relevant
(Table 2). Thus, our findings are in line with recently
published Cochrane reviews that summarize the general
positive effect of probiotics in preventing the infection
with acute respiratory disease [34, 35].
During the first 28 days, i.e., in a timely close correl-
ation with the EcN administration, no adverse event
could be detected in the group of children treated with
EcN. Thus, EcN can be assessed as safe and well toler-
ated by preterm newborns with a gestational age of 35–
36 weeks. In addition, the total number of adverse
events reported during the first year of life was compar-
ably low in both groups, being 28 and 30 in the EcN and
the control group, respectively. None of these adverse
events was judged as drug related. Similarly, children of
both groups showed a normal and comparable somatic
development. These data indicate that EcN treatment
bears no safety risks.
EcN is able to colonize the intestinal tract. It was de-
tected in the stool of adults up to 48 weeks [20] and in
the stool of healthy newborns up to 6 months after the
intake of EcN was stopped [24]. Therefore, it has been
suggested that the infection prophylactic effect of EcN
may even persist if the last EcN administration is already
some time ago. To investigate this explorative hypoth-
esis, variants of the primary efficacy variable, namely the
numbers of children that suffered from at least one ARI
during the first 6 and 12 months of life, were compared
between the EcN and the control group. Interestingly, it
appeared that the number of children with at least one
ARI was no longer different between the EcN and the
control group, neither after 6 nor after 12 months of age
(Table 2). Hence, a single EcN administration period, as
used in the present study, seems not sufficient to pre-
vent children from contracting a single ARI during the
first 6 months of life. Future studies may therefore con-
sider investigating whether a constant or at least re-
peated administration of EcN may be able to prolong
the infection-free period.
The exploratory analysis of the further secondary effi-
cacy variables led to additional interesting observations:
The average number of ARIs, the average number of
hospitalizations due to ARIs, and the mean duration of
these hospitalizations during the first 28 days of life all
Table 2 Results of the study of efficacy and safety of EcN for immunity improvement in late preterm newborns
After 28 days of life After 6 months of life After 12 months of life
EcN (N = 30) Control (N = 32) EcN (N = 30) Control (N = 32) EcN (N = 30) Control (N = 32)
Efficacy measures
Total number and % of
participants with at least 1 ARI
3 (10.0) 14 (43.7) 15 (50.0) 23 (71.9) 23 (76.7) 30 (93.8)
Χ2cor. = 7.25; p = 0.008 Χ2cor. = 2.27; p = 0.132 Χ2cor. = 1.32; p = 0.251
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z = 1.85, p = 0.06 z = 2.40, p = 0.02 z = 1.59, p = 0.11
RR 0.23 0.70 0.82
RRR 0.77 0.30 0.18
NNT 3 5 6
Safety measures
Total number of AEs 0 6 23 21 28 30
Total number of drug- related AEs 0 0 0 0 0 0
Mean body weight (g) N/A N/A 6623 ± 268 6419 ± 164 9765 ± 446 9634 ± 532
Mean body length (cm) N/A N/A 61.4 ± 1.1 61.2 ± 0.9 73.0 ± 1.2 73.3 ± 1.4
Data are numbers (%), means and CI, means ± SD, or epidemiological indices. Means of efficacy measures were always calculated from cumulative data. For
details, see the “Statistical analysis” section
% frequency, CI 95% confidence intervals, SD standard deviation, ARI acute respiratory infection, RR relative risk, RRR relative risk reduction, NNT number needed
to treat
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Fig. 4 Exploratory results of secondary efficacy measures. Shown are the mean numbers of ARIs (a), the mean numbers of hospitalizations due to ARIs
(b), and the mean durations of hospitalizations due to ARIs (c) after 28 days, 6 months, and 12 months for the EcN and the control group, respectively.
Error bars represent 95% confidence intervals. As statistical analyses of secondary efficacy variables are only performed for explorative purposes, given
p values are not corrected for α-error inflation
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tend to be reduced by an early treatment with EcN.
Overall, most of these trends seem to persist until the
ages of 6 and 12 months, making it possible to speculate
about a potential long-term benefit of an early postnatal
EcN treatment.
Although these findings are certainly interesting and
add to our knowledge of the health-promoting proper-
ties of EcN, it needs to be considered that they are just
of explorative nature. Similarly, limitations in the study
design, like, for example, the comparatively small sample
size or the fact that the study was not randomized and
open-labeled, must be taken into account when drawing
conclusions from the present data. Nonetheless, we be-
lieve that our findings provide good first evidence that
early-life EcN administration is able to prevent ARIs in
late preterm newborns. Therefore, our study may serve
as a good basis for the design of future larger trials that
should be conducted randomized, blinded, and placebo-
controlled in order to confirm the present findings
under the highest scientific standards.
Investigators planning such studies should also con-
sider adjustments and further development of the study
protocol. For example, it would be interesting to investi-
gate whether a constant or repeated administration of
EcN during the first year of life may be able to further
increase the infection prophylactic effects of EcN (see
above). In addition, it might be worth to also record data
on the duration and severity of the infections that occur,
as these data may allow a more detailed description of
the health-promoting properties of EcN. However, col-
lection of such data may require detailed written docu-
mentation by the parents at the time of the infection
(study diary) and systematic collection of medical re-
cords, in order to minimize the potential impact of recall
biases. Finally, it may be recommended to also record
data on other factors that are known to affect a child’s
susceptibility to acquiring infections. For example, the
duration of breastfeeding may act as a confounding vari-
able in the given context and should therefore be taken
into account in future studies, when analyzing the effi-
cacy of EcN to prevent ARIs in newborns, infants, and
toddlers.
Conclusions
In summary, our results provide the first evidence that
administration of EcN directly after birth can reduce the
risk of contracting an ARI in late preterm newborns dur-
ing the first month of their life. EcN suspension is char-
acterized by an excellent individual tolerance and the
absence of adverse drug reactions. Additional explorative
findings support the impression that EcN may be an ef-
fective and safe probiotic to prevent ARIs and may pro-
voke speculations about a potential long-term benefit of
a 3-week EcN administration starting right after birth.
Although the limitations of the current trial need to be
considered when drawing conclusions from the present
data, it may still serve as a good basis when preparing
future larger trials that are required to confirm the
present findings under the highest scientific standards.
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